Clinical Trials Logo

Hepatitis B, Chronic clinical trials

View clinical trials related to Hepatitis B, Chronic.

Filter by:

NCT ID: NCT02995252 Recruiting - Hepatitis C Clinical Trials

The HOPE Study: Characterizing Patients With Hepatitis B and C

Start date: December 2014
Phase:
Study type: Observational

This is an observational, longitudinal, prospective study for sample collection and evaluation for future therapy or disease progression of chronic hepatitis B and C. Participants will be seen on an annual basis with optional additional visits for up to 10 years and provide samples for research and evaluation of disease progression. In addition, there is a longitudinal sub-study for treatment of hepatitis B that will involve 2 years of treatment with tenofovir alafenamide and blood collections with optional liver biopsies.

NCT ID: NCT02992704 Active, not recruiting - Clinical trials for Chronic Hepatitis, B Virus

Peg-interferon for Inactive Chronic Hepatitis B Carriers

INACTIVE
Start date: August 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Chronic Hepatitis B carriers (normal LFTs and viral load < 2 x 10^4 IU/ml are not recommended to be treated by guidelines as they are at low risk for complications. However, it is unclear if treatment can enhance HBsAg loss which has been shown to be associated with significantly lower risk of complications compared to those without HBsAg loss. Consequently, this is a proof of concept study to determine the possibility of HBsAg loss in Chronic Hepatitis B carriers in a randomised open label clinical trial comparing no treatment to 24 weeks peg-interferon alpha 2a or 48 weeks peginterferon alpha 2a (randomised 1:1:1). The primary endpoint of HBsAg loss will be evaluated 24 weeks after the end of therapy for those on therapy and matched to an equivalent timepoint in the control arm. The sample size calculation is 30 patients in each arm for a 20% difference between any experimental arm and the control arm.

NCT ID: NCT02991638 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Start date: November 1, 2016
Phase: Phase 3
Study type: Interventional

Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers

NCT ID: NCT02982837 Recruiting - Hepatitis B Clinical Trials

To Study the Effect of Adding on Pegylated Interferon (PEG-INF) Therapy for Patients Diagnosed With Chronic Hepatitis B

RC14/055
Start date: March 2015
Phase: Phase 4
Study type: Interventional

To assess whether PEG-INF (Peglyated - interferon) Add-on therapy in patients of CHB who have achieved a maintained viral suppression (HBV DNA PCR( polymerase chain reaction) <200 for last 3-6 month) with NA's can result in increased rate of HBV infection eradication (HbsAg is undetectable by serological blood testing with or without seroconversion to HBs antibody).

NCT ID: NCT02981602 Completed - Hepatitis B Clinical Trials

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection

Start date: February 24, 2017
Phase: Phase 2
Study type: Interventional

To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection

NCT ID: NCT02979613 Completed - Chronic Hepatitis B Clinical Trials

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

Start date: December 29, 2016
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching to tenofovir alafenamide (TAF) versus continuing tenofovir disoproxil fumarate (TDF) in virologically suppressed adults with chronic hepatitis B virus (HBV) infection.

NCT ID: NCT02974829 Recruiting - Clinical trials for Hepatitis B, Chronic

REALM China Extension Study

Start date: May 2016
Phase: N/A
Study type: Observational

The purpose of this study is to conduct an investigator initiated observational study to continue to follow up the China subset of study participants for another 5 years after they complete participation in the REALM Study

NCT ID: NCT02973646 Recruiting - Chronic Hepatitis b Clinical Trials

Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection

Start date: January 2016
Phase: Phase 4
Study type: Interventional

The study is to observe the anti-HBV therapeutic effects of peginterferon alfa-2b in chronic hepatitis b patients with e antigen positive based on the detection of interferon gene mutation (IFNA2 p.Ala120Thr) and interferon receptor (IFNAR2) detection.

NCT ID: NCT02967939 Completed - Clinical trials for Hepatitis B, Chronic

Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

Start date: March 28, 2017
Phase: Phase 3
Study type: Interventional

A study demonstrates the non-inferiority of DA-2802 when compared with ć…¨Viread® in chronic hepatitis B patients

NCT ID: NCT02966964 Recruiting - Clinical trials for Hepatitis; Virus, Chronic, Type B

A Clinical Trials to Evaluate the Efficacy and Safety of Tenofovir With and Without DWPUR001 in Patients With HBV

Start date: April 2015
Phase: Phase 2
Study type: Interventional

The patient who meets the inclusion/exclusion criteria is assigned to Test1 group or Test 2 group or control group randomly. All subjects take one pill of Viread® Tab. (Tenofovir Disoproxil Fumarate 300mg) once a day for 48 weeks. At the same time, all randomized subjects take two pills of DWPUR001 or Placebo of DWPUR001 twice a day for 48 weeks.